-
Je něco špatně v tomto záznamu ?
Recent advances on smart glycoconjugate vaccines in infections and cancer
M. Anderluh, F. Berti, A. Bzducha-Wróbel, F. Chiodo, C. Colombo, F. Compostella, K. Durlik, X. Ferhati, R. Holmdahl, D. Jovanovic, W. Kaca, L. Lay, M. Marinovic-Cincovic, M. Marradi, M. Ozil, L. Polito, JJ. Reina, CA. Reis, R. Sackstein, A....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
Grantová podpora
LTC20078
Ministry of Education, Youth and Sports of the Czech Republic
CA18103
European Cooperation in Science and Technology
NLK
Free Medical Journals
od 2005 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 1 rokem
Wiley Free Content
od 2005 do Před 1 rokem
PubMed
33934527
DOI
10.1111/febs.15909
Knihovny.cz E-zdroje
- MeSH
- COVID-19 * prevence a kontrola MeSH
- glykokonjugáty terapeutické užití MeSH
- lidé MeSH
- nádory * prevence a kontrola MeSH
- polysacharidy terapeutické užití MeSH
- SARS-CoV-2 MeSH
- vakcíny * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as "tumor-associated carbohydrate antigens". Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
Blood Transfusion Center of Slovenia Ljubljana Slovenia
Departamento de Química Orgánica Universidad de Málaga IBIMA Spain
Department of Biochemistry Faculty of Science Charles University Prague Czech Republic
Department of Chemistry 'Ugo Schiff' University of Florence Sesto Fiorentino Italy
Department of Chemistry and CRC Materiali Polimerici University of Milan Italy
Department of Medical Biotechnology and Translational Medicine University of Milan Milano Italy
Department of Microbiology and Parasitology Jan Kochanowski University Kielce Poland
Faculty of Arts and Sciences Department of Chemistry Recep Tayyip Erdogan University Rize Turkey
I3S Instituto de Investigação e Inovação em Saúde Universidade do Porto Portugal
Institute of Biomolecular Chemistry Pozzuoli Italy
Instituto de Ciências Biomédicas Abel Salazar University of Porto Portugal
IPATIMUP Institute of Molecular Pathology and Immunology University of Porto Portugal
National Research Council CNR SCITEC Milan Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025314
- 003
- CZ-PrNML
- 005
- 20221031100132.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/febs.15909 $2 doi
- 035 __
- $a (PubMed)33934527
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Anderluh, Marko $u Faculty of Pharmacy, Faculty of Pharmacy, Chair of Pharmaceutical Chemistry, University of Ljubljana, Slovenia
- 245 10
- $a Recent advances on smart glycoconjugate vaccines in infections and cancer / $c M. Anderluh, F. Berti, A. Bzducha-Wróbel, F. Chiodo, C. Colombo, F. Compostella, K. Durlik, X. Ferhati, R. Holmdahl, D. Jovanovic, W. Kaca, L. Lay, M. Marinovic-Cincovic, M. Marradi, M. Ozil, L. Polito, JJ. Reina, CA. Reis, R. Sackstein, A. Silipo, U. Švajger, O. Vaněk, F. Yamamoto, B. Richichi, SJ. van Vliet
- 520 9_
- $a Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as "tumor-associated carbohydrate antigens". Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
- 650 12
- $a COVID-19 $x prevence a kontrola $7 D000086382
- 650 _2
- $a glykokonjugáty $x terapeutické užití $7 D006001
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory $x prevence a kontrola $7 D009369
- 650 _2
- $a polysacharidy $x terapeutické užití $7 D011134
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 12
- $a vakcíny $7 D014612
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Berti, Francesco $u Technical R&D, GSK Vaccines S.r.l., Siena, Italy
- 700 1_
- $a Bzducha-Wróbel, Anna $u Department of Biotechnology and Food Microbiology, Warsaw University of Life Sciences-SGGW, Warszawa, Poland
- 700 1_
- $a Chiodo, Fabrizio $u Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands $u Institute of Biomolecular Chemistry (ICB), Italian National Research Council (CNR), Pozzuoli, Italy
- 700 1_
- $a Colombo, Cinzia $u Department of Chemistry and CRC Materiali Polimerici (LaMPo), University of Milan, Italy
- 700 1_
- $a Compostella, Federica $u Department of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy
- 700 1_
- $a Durlik, Katarzyna $u Department of Microbiology and Parasitology, Jan Kochanowski University, Kielce, Poland
- 700 1_
- $a Ferhati, Xhenti $u Department of Chemistry 'Ugo Schiff', University of Florence, Sesto Fiorentino, Italy
- 700 1_
- $a Holmdahl, Rikard $u Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
- 700 1_
- $a Jovanovic, Dragana $u Vinča Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Serbia
- 700 1_
- $a Kaca, Wieslaw $u Department of Microbiology and Parasitology, Jan Kochanowski University, Kielce, Poland
- 700 1_
- $a Lay, Luigi $u Department of Chemistry and CRC Materiali Polimerici (LaMPo), University of Milan, Italy
- 700 1_
- $a Marinovic-Cincovic, Milena $u Vinča Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Serbia
- 700 1_
- $a Marradi, Marco $u Department of Chemistry 'Ugo Schiff', University of Florence, Sesto Fiorentino, Italy
- 700 1_
- $a Ozil, Musa $u Faculty of Arts and Sciences, Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey
- 700 1_
- $a Polito, Laura $u National Research Council, CNR-SCITEC, Milan, Italy
- 700 1_
- $a Reina, Josè Juan $u Departamento de Química Orgánica, Universidad de Málaga-IBIMA, Spain $u Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Parque Tecnológico de Andalucía, Málaga, Spain
- 700 1_
- $a Reis, Celso A $u I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal $u IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Portugal $u Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal
- 700 1_
- $a Sackstein, Robert $u Department of Translational Medicine, Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
- 700 1_
- $a Silipo, Alba $u Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte Sant'Angelo, Napoli, Italy $1 https://orcid.org/https://orcid.org/0000000253946532
- 700 1_
- $a Švajger, Urban $u Blood Transfusion Center of Slovenia, Ljubljana, Slovenia
- 700 1_
- $a Vaněk, Ondřej $u Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic $1 https://orcid.org/https://orcid.org/0000000311908535
- 700 1_
- $a Yamamoto, Fumiichiro $u Immunohematology & Glycobiology Laboratory, Josep Carreras Leukaemia Research Institute, Badalona, Spain
- 700 1_
- $a Richichi, Barbara $u Department of Chemistry 'Ugo Schiff', University of Florence, Sesto Fiorentino, Italy $1 https://orcid.org/https://orcid.org/0000000170939513
- 700 1_
- $a van Vliet, Sandra J $u Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands $1 https://orcid.org/https://orcid.org/0000000318112687
- 773 0_
- $w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 289, č. 14 (2022), s. 4251-4303
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33934527 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100130 $b ABA008
- 999 __
- $a ok $b bmc $g 1854830 $s 1176604
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 289 $c 14 $d 4251-4303 $e 20210601 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
- GRA __
- $a LTC20078 $p Ministry of Education, Youth and Sports of the Czech Republic
- GRA __
- $a CA18103 $p European Cooperation in Science and Technology
- LZP __
- $a Pubmed-20221017
